News Releases Keyword Search Year None20232022202120202019201820172016 Aug-02-2022 Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results Jul-14-2022 Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in combination with Ibrutinib for Patients with MCL Jun-10-2022 Oncternal Therapeutics Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress Jun-10-2022 Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 Congress Jun-02-2022 Oncternal Therapeutics to Participate in the Jefferies Healthcare Conference 2022 Jun-01-2022 Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) May-26-2022 Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022 May-05-2022 Oncternal Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results May-02-2022 Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Apr-28-2022 Oncternal Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »